Continuing Medical Education Accreditation
The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.
The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 hours of Category 1 CME credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity.
Continuing Pharmacy Education Accreditation
is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEU) under the ACPE universal program number of 290-000-03-014-H01.
After reading "Erectile Dysfunction in the Patient With Diabetes Mellitus," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (a minimum score of 70%) the examination at the conclusion of the program.
1. Which of the following is true regarding the formation of a normal erection?
2. A decreased level of nitric oxide synthase in which of the following cells can lead to erectile dysfunction (ED)?
3. Relaxation of vascular smooth muscle of the corpora cavernosa is not facilitated by:
4. Which of the following classes of drugs are likely causes of ED?
5. Documented beneficial therapy for erectile dysfunction in diabetes mellitus (EDDM) includes all of the following except:
6. Which of the following hormonal replacement options is not recommended in a patient with androgen-deficiency ED?
7. Which of the following is not a first-line therapy for EDDM?
8. Use of a VCD is not limited by:
9. Which of the following oral agents is comparable to the phosphodiesterease type 5 (PDE-5) inhibitors as an effective treatment of EDDM?
10. Sildenafil is effective in the treatment of EDDM because it:
11. Which of the following statements concerning PDE-5 inhibitors is/are true?
12. Efficacy of PDE-5 inhibitors is dependent on all of the following factors except:
13. Which side effect(s) has/have been reported with all 3 PDE-5 inhibitors?
14. Which of the following statements is true regarding the pharmacokinetics of PDE-5 inhibitors?
15. Unstable angina, ventricular arrhythmias, and congestive heart failure are:
16. Prostaglandin E-1 MUSE is not acceptable for use in which of the following patients?
17. Candidates for intracavernosal injections include:
18. Patients who do not improve after first- or second-line therapy with pharmacologic therapy are candidates for which of the following third-line options?
19. Which of the following statements regarding combination therapy in EDDM patients is true?
20. When counseling a patient on the use of oral PDE-5 inhibitor therapy, a pharmacist should:
ANSWER CARD INSTRUCTIONS
Testing and Grading Procedures
Please photocopy the test form for additional test takers
is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-000-03-014-H01. The program is available for CE credit through January 31, 2007.